The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

Recruiting

• Conditions: Multiple Myeloma; Germ Cell Neoplasms; Acute Myelogenous Leukemia; Non-Hodgkin's Lymphoma; Myelodysplastic Syndromes; Hodgkin's Disease; Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Immunodeficiency Diseases

• Registration Number: NCT01890486
• Lead Sponsor: Wake Forest University Health Sciences

Brief Summary

To provide the IRB approved mechanism for the prospective collection, analysis and reporting of data on patients who are undergoing either an autologous or allogeneic hematopoietic stem cell transplant for a disease in which a research question is not being addressed and for which peer reviewed, published data have demonstrated efficacy for this treatment approach.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2001-05-21
• Study First Submitted: 2013-06-27
• Study First Submitted QC: 2013-06-27
• Study First Posted: 2013-07-01
• Status Verified: 2024-06
• Last Update Submitted: 2024-06-10
• Last Update Posted: 2024-06-12
• Primary Completion: 2025-12
• Study Completion: 2025-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 2000

Inclusion Criteria

Planned standard of care dose intensive therapy and either an allogeneic or autologous bone marrow transplant

Read More

Exclusion Criteria

Participation in any other treatment research protocol

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Data followup	1 year	Gather basic survival and complication data for operational and research databases for ongoing regulatory and future operational queries

Trial Locations

Locations (1)

Wake Forest Baptist Health; 🇺🇸 Winston-Salem, North Carolina, United States